White HD， Chew DP， Hoekstra JW， Miller CD， Pollack CV Jr， Feit F， Lincoff AM， Bertrand M， Pocock S， Ware J， Ohman EM， Mehran R， Stone GW.
Green Lane Cardiovascular Service， Auckland City Hospital， Auckland， New Zealand. HarveyW@adhb.govt.nz
Abstract
OBJECTIVES: The aim of this study was to compare outcomes in patients receiving consistent unfractionated heparin (UFH)/enoxaparin (ENOX) therapy and in those switched at randomization to bivalirudin monotherapy.
BACKGROUND: Crossover between UFH and ENOX has been associated with increased adverse outcomes in patients with acute coronary syndromes. The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demonstrated superior net clinical outcomes with similar rates of ischemia and significantly less major bleeding with bivalirudin monotherapy compared with UFH/ENOX plus a glycoprotein (GP) IIb/IIIa inhibitor. It is unknown if these results would be preserved in patients switched from UFH/ENOX to bivalirudin monotherapy.
METHODS: We compared composite ischemia， major bleeding， and net clinical outcomes at 30 days in patients receiving consistent UFH/ENOX therapy and in those switched at randomization from pre-treatment with UFH/ENOX to bivalirudin monotherapy. We also compared outcomes in patients naive to antithrombin therapy who were randomized to UFH/ENOX or bivalirudin monotherapy.
RESULTS: Two thousand one hundred thirty-seven patients received consistent UFH/ENOX (UFH n = 1，294， ENOX n = 843)， and 2，078 patients pre-treated with UFH/ENOX were switched to bivalirudin. Patients switching to bivalirudin had similar rates of ischemia (6.9% vs. 7.4%， p = 0.52)， less major bleeding (2.8% vs. 5.8%， p < 0.01)， and improved net clinical outcomes (9.2% vs. 11.9%， p < 0.01) than those on consistent UFH/ENOX plus a GP IIb/IIIa inhibitor. Patients naive to antithrombin therapy who were administered bivalirudin (n = 1，427) had similar rates of ischemia (6.2% vs. 5.5%， p = 0.47)， less major bleeding (2.5% vs. 4.9%， p < 0.001)， and similar net clinical outcomes (8.0% vs. 9.4%， p = 0.17) compared with naive patients administered UFH/ENOX plus a GP IIb/IIIa inhibitor (n = 1，462).
CONCLUSIONS: Switching from UFH/ENOX to bivalirudin monotherapy results in comparable ischemic outcomes and an approximately 50% reduction in major bleeding compared with consistent UFH/ENOX plus a GP IIb/IIIa inhibitor. Patients naive to antithrombin therapy administered bivalirudin monotherapy had a significant reduction in bleeding and similar rates of ischemia compared with naive patients initiated with UFH or ENOX plus a GP IIb/IIIa inhibitor.